Unknown

Dataset Information

0

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.


ABSTRACT: ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X(L). Meayamycin B switches the splicing pattern of myeloid cell leukemia factor 1 (MCL1) pre-mRNA. Specifically, inhibition of splicing factor 3B subunit 1 (SF3B1) with meayamycin B promotes the generation of the proapoptotic, short splicing variant (MCL1-S) and diminishes the antiapoptotic, long variant (MCL1-L). This action was previously associated with the cytotoxicity of meayamycin B in non-small cell lung carcinoma cell lines. ABT-737 induced apoptosis in response to an ablation of MCL1-L by meayamycin B. In this study, we further exploited this synergistic combination in head and neck squamous cell carcinoma (HNSCC), up to 90% of which overexpress MCL1 and BCL-X(L). In a panel of seven HNSCC cell lines, the combination of meayamycin B and ABT-737 rapidly triggered a Bax/Bak-mediated apoptosis that overcame the resistance from HPV16-positive HNSCC against each agent alone. Both RT-PCR and Western blotting showed that meayamycin B up-regulated MCL1-S and down-regulated MCL1-L. Significantly, we discovered that SF3B1 was involved in the splicing of oncogenic HPV16 E6 to produce non-oncogenic HPV16 E6*, indicating that SF3B1 may inhibit HPV16-induced tumorigenesis.

SUBMITTER: Gao Y 

PROVIDER: S-EPMC4138523 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.

Gao Yang Y   Trivedi Sumita S   Ferris Robert L RL   Koide Kazunori K  

Scientific reports 20140820


ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X(L). Meayamycin B switches the splicing pattern of myeloid cell leukemia factor 1 (MCL1) pre-mRNA. Specifically, inhibition of splicing factor 3B subunit 1 (SF3B1) with meayamycin B promotes the generation of the proapoptotic, short splicing variant (MCL1-S) and diminishes the antiapoptotic, long variant (MCL1-L). This action was previously associated with the cytotoxicity of meayamycin B in non-small cell lung carci  ...[more]

Similar Datasets

| S-EPMC6537867 | biostudies-literature
| S-EPMC3428689 | biostudies-literature
| S-EPMC4625038 | biostudies-literature
| S-EPMC3912227 | biostudies-literature
| S-EPMC4751247 | biostudies-literature
| S-EPMC5930384 | biostudies-literature
| S-EPMC7698015 | biostudies-literature
| S-EPMC3111202 | biostudies-literature
| S-EPMC5482618 | biostudies-literature
| S-EPMC5322843 | biostudies-literature